DE69212646T2 - Zubereitung und verfahren enthaltend optisch reines s-metoprolol - Google Patents

Zubereitung und verfahren enthaltend optisch reines s-metoprolol

Info

Publication number
DE69212646T2
DE69212646T2 DE69212646T DE69212646T DE69212646T2 DE 69212646 T2 DE69212646 T2 DE 69212646T2 DE 69212646 T DE69212646 T DE 69212646T DE 69212646 T DE69212646 T DE 69212646T DE 69212646 T2 DE69212646 T2 DE 69212646T2
Authority
DE
Germany
Prior art keywords
metoprolol
optically pure
preparation
process containing
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69212646T
Other languages
English (en)
Other versions
DE69212646D1 (de
Inventor
James W Young
Timothy J Barberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69212646D1 publication Critical patent/DE69212646D1/de
Publication of DE69212646T2 publication Critical patent/DE69212646T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/40—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups and esterified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/10—Saturated ethers of polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/164—Unsaturated ethers containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69212646T 1991-03-18 1992-03-10 Zubereitung und verfahren enthaltend optisch reines s-metoprolol Expired - Fee Related DE69212646T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67099591A 1991-03-18 1991-03-18
PCT/US1992/001950 WO1992016197A1 (en) 1991-03-18 1992-03-10 Composition and method containing optically pure (s) metoprolol

Publications (2)

Publication Number Publication Date
DE69212646D1 DE69212646D1 (de) 1996-09-12
DE69212646T2 true DE69212646T2 (de) 1997-03-13

Family

ID=24692726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69212646T Expired - Fee Related DE69212646T2 (de) 1991-03-18 1992-03-10 Zubereitung und verfahren enthaltend optisch reines s-metoprolol

Country Status (11)

Country Link
US (1) US5362757A (de)
EP (2) EP0677291A3 (de)
JP (1) JPH0825927B2 (de)
AT (1) ATE141049T1 (de)
AU (1) AU660984B2 (de)
CA (1) CA2106494A1 (de)
DE (1) DE69212646T2 (de)
DK (1) DK0576617T3 (de)
ES (1) ES2093833T3 (de)
GR (1) GR3021543T3 (de)
WO (1) WO1992016197A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335213A (en) 1996-11-20 2001-02-23 Astra Ab Metoprolol and a method of preparing metoprolol by reacting p-(2-methoxyethyl)phenol and epichlorohydrin and isopropylamine
KR100332399B1 (ko) * 1999-02-22 2002-04-13 김경호 메토프롤롤 라세미체로부터 메토프롤롤 에난티오머의 제조방법
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
JP2007522203A (ja) * 2004-02-11 2007-08-09 アスファーマ・リミテッド 時間療法用組成物とそれらの使用方法
JP2006182740A (ja) * 2004-12-28 2006-07-13 Daiso Co Ltd グリシジルスルホナート誘導体の製造法
EP2444077A1 (de) 2007-01-29 2012-04-25 Vlife Sciences Technologies Pvt Ltd. Pharmazeutische Zusammensetzung zur Behandlung von diabetischen Komplikationen
CN101254182B (zh) * 2008-03-10 2010-09-08 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物
CN101732248B (zh) * 2010-01-20 2011-08-17 白求恩医科大学制药厂 一种酒石酸美托洛尔注射液及其制备方法
CN108853071A (zh) 2012-02-16 2018-11-23 萨尼奥纳有限责任公司 用于联合治疗的药物组合物
KR101379383B1 (ko) * 2012-03-23 2014-04-02 주식회사 알에스텍 고순도 ⒮―메토프롤롤의 제조방법
WO2016138908A1 (en) 2015-03-03 2016-09-09 Saniona A/S Tesofensine, beta blocker combination formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404073D0 (sv) * 1984-08-13 1984-08-13 Haessle Ab Method for the synthesis of pharmacologically acitve compounds and intermediates for such synthesis
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
DE3725273A1 (de) * 1987-07-30 1989-02-09 Basf Ag Verfahren zur synthese von enantiomeren des propafenons sowie diese enthaltende therapeutische mittel
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
JPH037217A (ja) * 1989-03-28 1991-01-14 Nitto Denko Corp メトプロロール含有テープ製剤
JPH0311014A (ja) * 1989-06-08 1991-01-18 Nisshin Oil Mills Ltd:The 外用ゲル製剤

Also Published As

Publication number Publication date
EP0677291A3 (de) 1996-08-07
EP0677291A2 (de) 1995-10-18
ES2093833T3 (es) 1997-01-01
JPH0825927B2 (ja) 1996-03-13
GR3021543T3 (en) 1997-02-28
DK0576617T3 (da) 1996-12-30
CA2106494A1 (en) 1992-09-19
US5362757A (en) 1994-11-08
AU660984B2 (en) 1995-07-13
EP0576617A1 (de) 1994-01-05
WO1992016197A1 (en) 1992-10-01
ATE141049T1 (de) 1996-08-15
AU1774192A (en) 1992-10-21
JPH06505994A (ja) 1994-07-07
EP0576617B1 (de) 1996-08-07
DE69212646D1 (de) 1996-09-12

Similar Documents

Publication Publication Date Title
ATE141049T1 (de) Zubereitung und verfahren enthaltend optisch reines s-metoprolol
FI892823A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen (S)-1-(3-dimetyyliaminopropyyli)-1-(4'-fluorifenyyli)-1,3-dihydrobentsofuraani-5-karbonitriilin valmistamiseksi
CA2073181A1 (en) Optically pure r(-) albuterol for treating asthma
NO169492C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2',3'-dideoksy-2'-fluornukleosider
NO901989L (no) Fremgangsmaate for fremstilling av maleinimidderivater.
DE69407785T2 (de) Benzoylbenzofuranderivate zur behandlung von herzarrhythmia
EP0424525A4 (de) Amine und deren verwendung.
AU1213892A (en) Novel 8-substituted purines as selective adenosine receptor agents
BG103934A (en) (+)-norcisaprid used in disorder with 5-ht3 and 5-ht4 mediates
DE59010435D1 (de) Indolocarbazol-Derivate, Verfahren zu deren Herstellung und deren Verwendung
FI93117C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 9-aminotetrahydroakridiinijohdannaisten valmistamiseksi
FI910895A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen 4-(di-n-propyyli)amino-6-aminokarbonyyli-1,3,4,5-tetrahydrobentso/c,d/indolihippuraatin valmistam iseksi
ATE50571T1 (de) Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
EP1013278A4 (de) Kiefernnadelextrakt sowie dessen verwendung
NO913188L (no) Fremgangsmaate ved fremstilling av enantiomert rene polysubstituerte 1,4-dihydropyridiner.
DK478585A (da) 4-alkoxy-pyrido(2,3-d)pyrimidin-derivater, deres fremstilling og anvendelse
AU4720389A (en) N-pyridinyl-9h-carbazol-9-amines, a process their preparation and their use as medicaments
NO177264C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, kondenserte benzazepiner, samt forbindelser for anvendelse som mellomprodukter ved analogifremgangsmåten
SE8600786D0 (sv) Ergolinderivat och syraadditionssalter derav
FI873843A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4-C-hydroksi-2-r-(substituoitu)kromaani-4-etikkahappojohdannaisten valmistamiseksi
IL92307A0 (en) Hydroxy-1,2,3,4-tetrahydroamino-acridines,a process for their preparation and pharmaceutical compositions containing them
CU22713A3 (es) Procedimiento de obtencion del compuesto 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetilpiridin-3,5-dicarboxilato de isopropilo y 2-metoxietilo
WO1989010917A3 (fr) Nouveaux inhibiteurs de la renine, leur procede de fabrication et leur emploi
AU7196987A (en) 1,4-dihydropyridine derivatives, process for their preparation and medicaments containing these compounds
GR3024707T3 (en) Digitoxigenin and dihydrodigitoxigenin 3beta-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee